Top-line results from the Phase Ib study with YELIVA (ABC294640) in patients with advanced solid tumors are expected to be announced in the coming weeks
Nomura's specialty pharmaceuticals and generics industry analyst, initiated coverage of the sector with five Buy-rated recommendations.
eines davon ist halt RDHL
RedHill Biopharma Ltd ADR (NASDAQ: RDHL) currently has three phase III candidates with a total market opportunity of $10.3 billion. Accordingly, the stock represents an "attractive" long-term investment.